PH

Parker-Hannifin is a genuinely high-quality compounder, and the FY2025 numbers show it. Return on equity is 25.8%, operating margin is 21.9%, and gross margin expanded to 36.9% from 35.8% (per MD&A) on price increases, favorable mix, cost containment and continued Win Strategy execution. The model converts to cash: operating cash flow rose 11.6% to $3.78B against $435M of capex (~$3.35B free cash flow), funding $1.77B of buybacks (+431.9%) and $861M of dividends (+10.1%) while still de-risking the balance sheet — long-term debt fell 10.8% to $7.50B, the current portion of debt was nearly eliminated, equity grew 13.3%, and liabilities/equity sits at a comfortable 1.16x. Lower average debt also cut interest expense to $409M from $506M, a real, recurring tailwind.

The catch is that growth is decelerating and the headline earnings are flattered. Revenue actually slipped 0.4% and has been flat near $19.9B for two years. The Diversified Industrial Segment shrank to $13,665M from $14,458M, with North America down 7.6% as reported (~-3.7% organic after divestitures and currency), and — most telling — segment backlog fell to $3,655M from $4,182M, a leading indicator of softening industrial demand. Meanwhile the eye-catching +24% EPS overstates underlying momentum: operating income grew only 6.8%. The gap came from the effective tax rate dropping to 14.0% from 20.9% (a foreign valuation-allowance release and other discrete items) plus a $273M gain on business sales versus just $12M a year earlier. Tax normalization back toward the 21% statutory rate is a plausible future headwind to EPS that the multiple does not seem to account for.